KD Pharma acquires Switzerland-based cannabinoid manufacturer PhytoXtract
The global CMO plans to have a complete, licensed cGMP manufacturing facility online by the end of 2021
KD Pharma has acquired the manufacturing assets of Switzerland-based cannabinoid manufacturer, PhytoXtract, giving the contract manufacturing organisation access to technology for producing active pharmaceutical ingredients (APIs) based on phytocannabinoids and other plant extracts.
The technology further expands KD Pharma’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies.
Although the company specialises in lipid technology focused primarily on omega-3s, its technology suites can be applied to other lipid sources such as cannabinoids.
The assets from Phytoextract will provide KD Pharma with additional routes to develop new products for this emerging market.
Last June, KD Pharma signed a licensing agreement with Italy-based Herbolea Biotech for Bio-Herbolysis, a novel extraction method, that can process 300 kg/hour, in one process step, without the need for solvent.
KD Pharma expects to have a complete, licensed cGMP manufacturing facility online by the end of the year.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance